205 related articles for article (PubMed ID: 10921249)
1. [The comparative characteristics of the renal protective properties of angiotensin-converting enzyme inhibitors and calcium channel blockers].
Kolesnyk MO; Lapchyns'ka II; Hromova AIe; Kassyr KhI
Lik Sprava; 2000; (3-4):11-5. PubMed ID: 10921249
[No Abstract] [Full Text] [Related]
2. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
Bauer JH; Reams GP
J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
Linas S
Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
[TBL] [Abstract][Full Text] [Related]
4. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
[TBL] [Abstract][Full Text] [Related]
5. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
[TBL] [Abstract][Full Text] [Related]
6. [Diabetes mellitus and hypertension: calcium antagonists or ACE inhibitors?].
Jungmann E
Dtsch Med Wochenschr; 1991 May; 116(22):859-62. PubMed ID: 2036945
[No Abstract] [Full Text] [Related]
7. [The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases].
Kutyrina IM; Tareeva IE; Gerasimenko OI; Rogov VA; Miroshnichenko NG
Ter Arkh; 1995; 67(5):20-3. PubMed ID: 7638769
[TBL] [Abstract][Full Text] [Related]
8. The effect of angiotensin converting enzyme inhibition on effective renal plasma flow in patients with diffuse renal parenchymal diseases and hypertension.
Zeravica R; Stosić Z; Ilincić B; Crnobrnja V; Jakovljević A; Mijović R
Med Pregl; 2014; 67(3-4):78-82. PubMed ID: 24961048
[TBL] [Abstract][Full Text] [Related]
9. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
[TBL] [Abstract][Full Text] [Related]
10. Calcium channel blockers in the prevention of end stage renal disease: a review.
Derwa A; Peeters P; Vanholder R
Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
[TBL] [Abstract][Full Text] [Related]
11. REIN on obesity, proteinuria and CKD.
Choi ME
J Am Soc Nephrol; 2011 Jun; 22(6):990-2. PubMed ID: 21617125
[No Abstract] [Full Text] [Related]
12. Calcium channels blockers and progression of kidney disease.
Ziakka S; Kaperonis N; Ferentinou E; Karakasis F; Ntatsis G; Kourvelou C; Papagalanis N
Ren Fail; 2007; 29(8):1003-12. PubMed ID: 18067048
[TBL] [Abstract][Full Text] [Related]
13. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
Jain AK; Cuerden MS; McLeod I; Hemmelgarn B; Akbari A; Tonelli M; Quinn RR; Oliver MJ; Garg AX
Kidney Int; 2012 Jun; 81(12):1248-53. PubMed ID: 22437415
[TBL] [Abstract][Full Text] [Related]
14. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease.
Omae K; Ogawa T; Nitta K
Heart Vessels; 2009 Jul; 24(4):301-7. PubMed ID: 19626404
[TBL] [Abstract][Full Text] [Related]
15. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
[TBL] [Abstract][Full Text] [Related]
16. [Do angiotensin converting enzyme and calcium channel blocker intervene in the progression of renal disease besides by lowering systemic hypertension?].
Nagase M
Nihon Rinsho; 1997 Aug; 55(8):2116-22. PubMed ID: 9284433
[TBL] [Abstract][Full Text] [Related]
17. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy.
Okamura M; Kanayama Y; Negoro N; Inoue T; Takeda T
Contrib Nephrol; 1991; 90():161-5. PubMed ID: 1959342
[TBL] [Abstract][Full Text] [Related]
19. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.
Mahajan A; Simoni J; Sheather SJ; Broglio KR; Rajab MH; Wesson DE
Kidney Int; 2010 Aug; 78(3):303-9. PubMed ID: 20445497
[TBL] [Abstract][Full Text] [Related]
20. Systemic hypertension and antihypertensive agents.
Maschio G; Marcantoni C; Bernich P
J Nephrol; 1999; 12 Suppl 2():S100-4. PubMed ID: 10688408
[No Abstract] [Full Text] [Related]
[Next] [New Search]
